{"id":"https://openalex.org/W2024920292","doi":"https://doi.org/10.5414/cpp40524","title":"Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects","display_name":"Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects","publication_year":2002,"publication_date":"2002-11-01","ids":{"openalex":"https://openalex.org/W2024920292","doi":"https://doi.org/10.5414/cpp40524","mag":"2024920292","pmid":"https://pubmed.ncbi.nlm.nih.gov/12698990"},"language":"en","primary_location":{"id":"doi:10.5414/cpp40524","doi":"https://doi.org/10.5414/cpp40524","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cpp40524","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018533252","display_name":"G\u00e9rard Flesch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"G. Flesch","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland, gerard_jp.flesch@pharma.novartis.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland, gerard_jp.flesch@pharma.novartis.com","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113100926","display_name":"D Tudor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Tudor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034214149","display_name":"Claire Souppart","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Souppart","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113656190","display_name":"J. D\u2019Souza","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. D\u2019Souza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5029988616","display_name":"Mohammad Sharif Hossain","orcid":"https://orcid.org/0000-0002-9876-7722","observed_orcids":["https://orcid.org/0000-0002-9876-7722"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Hossain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6514,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.69442553,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"40","issue":"11","first_page":"524","last_page":"532"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.44190001487731934,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.44190001487731934,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.19699999690055847,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.14010000228881836,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oxcarbazepine","display_name":"oxcarbazepine","score":1.0},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.8429999947547913},{"id":"https://openalex.org/keywords/tablet-formulation","display_name":"tablet formulation","score":0.8149999976158142},{"id":"https://openalex.org/keywords/marketed-formulations","display_name":"marketed formulations","score":0.7509999871253967},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.875},{"id":"https://openalex.org/keywords/plasma-auc","display_name":"plasma AUC","score":0.5210000276565552},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.7039999961853027},{"id":"https://openalex.org/keywords/formulation-change","display_name":"formulation change","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.9206075668334961},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6892776489257812},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.648575484752655},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6073805093765259},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.5932247638702393},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.578376293182373},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5443255305290222},{"id":"https://openalex.org/C19720800","wikidata":"https://www.wikidata.org/wiki/Q7722","display_name":"Morning","level":2,"score":0.5314124226570129},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45850756764411926},{"id":"https://openalex.org/C2781176495","wikidata":"https://www.wikidata.org/wiki/Q176301","display_name":"Oxcarbazepine","level":4,"score":0.4137091636657715},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22662967443466187},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.1600097417831421},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.06371286511421204},{"id":"https://openalex.org/C2779253243","wikidata":"https://www.wikidata.org/wiki/Q410412","display_name":"Carbamazepine","level":3,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000078330","descriptor_name":"Oxcarbazepine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003984","descriptor_name":"Dibenzazepines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.5414/cpp40524","doi":"https://doi.org/10.5414/cpp40524","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cpp40524","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:12698990","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12698990","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical pharmacology and therapeutics","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1980468546","https://openalex.org/W1984810907","https://openalex.org/W2351790274","https://openalex.org/W7045982699","https://openalex.org/W2098482900","https://openalex.org/W2027660222","https://openalex.org/W7119393660","https://openalex.org/W2616390897","https://openalex.org/W3169941608","https://openalex.org/W7219884069"],"abstract_inverted_index":{"A":[0,109],"final":[1,69,110,325],"market":[2,16,70,320,326],"image":[3,327],"(FMI)":[4,253],"tablet":[5,26,328],"formulation":[6,14,17,24,162,252,263,321],"of":[7,36,51,63,85,89,112,144,149,219,308],"oxcarbazepine":[8],"was":[9,39,65,74,115,163,177,227,233,238,254,336],"compared":[10,164,179],"with":[11,20,165,180,259,265,282,294],"the":[12,21,37,42,52,61,68,118,166,217,236,241,260,306,309,315,318,324,330],"marketed":[13,262],"(current":[15],"(CMF))":[18],"and":[19,31,47,56,131,136,168,194,208,258,269,278,286,288,290],"clinical":[22,29],"trial":[23],"(CTF)":[25],"used":[27,215,228],"during":[28],"efficacy":[30],"safety":[32],"studies.":[33],"The":[34,72,221],"goal":[35],"study":[38,73],"to":[40,100,256,267,284,296,323],"compare":[41],"bioavailability":[43,307],"after":[44],"single":[45,87,201,272],"doses":[46],"at":[48],"steady":[49,195,206,246],"state":[50,196,247],"FMI":[53,159,173,181,277,289],"versus":[54],"CMF":[55,167,291],"CTF":[57,169,257,279],"as":[58,160,170],"well.":[59],"Additionally,":[60],"effect":[62,304],"food":[64],"evaluated":[66],"on":[67,93,120,127,132,137,305],"formulation.":[71],"an":[75],"open-label,":[76],"single-center,":[77],"4-way":[78],"crossover":[79],"trial.":[80],"Each":[81],"treatment":[82],"period":[83],"consisted":[84],"a":[86,155],"dose":[88,111,202,273],"600":[90,104,113],"mg":[91,105,114],"OXC":[92],"Day":[94,97,102,121,128,133,138],"1.":[95],"From":[96],"4":[98],"up":[99],"including":[101],"7,":[103],"b.i.d.":[106],"were":[107,125,151,187,214,280,292],"administered.":[108],"administered":[116],"in":[117,329],"morning":[119],"8.":[122],"Blood":[123],"samples":[124],"taken":[126],"1":[129],"before":[130],"7":[134],"(predose)":[135],"8":[139],"(morning":[140],"dose).":[141],"Plasma":[142,198],"concentrations":[143],"MHD":[145],"(the":[146],"main":[147],"metabolite":[148],"OXC)":[150],"determined":[152],"by":[153],"using":[154,189],"validated":[156],"HPLC":[157],"assay.":[158],"test":[161],"reference":[171,261],"formulations.":[172],"under":[174,182,248,274],"fed":[175,249,275],"conditions":[176],"also":[178],"fasting":[183],"conditions.":[184,197],"These":[185,311],"comparisons":[186],"made":[188],"data":[190],"following":[191],"single-dose":[192],"administration":[193],"AUC":[199,268,285,297],"for":[200,205,216,229],"or":[203,335],"AUC(0-12h)":[204],"state,":[207],"plasma":[209],"Cmax,":[210,287],"log-transformed":[211],"(natural":[212],"base),":[213],"assessment":[218],"bioequivalence.":[220,231],"90%":[222],"confidence":[223],"interval":[224],"(CI)":[225],"approach":[226],"testing":[230],"Bioequivalence":[232],"accepted":[234],"if":[235],"CI":[237],"contained":[239],"within":[240],"region":[242],"(0.8,":[243],"1.25).":[244],"At":[245],"conditions,":[250,276],"tested":[251],"bioequivalent":[255,281],"(CMF)":[264,322],"regard":[266,283,295],"Cmax.":[270,300],"After":[271],"equivalent":[293],"but":[298],"not":[299],"Food":[301],"had":[302],"no":[303],"FMI.":[310],"results":[312],"clearly":[313],"support":[314],"switch":[316],"from":[317],"current":[319],"countries":[331],"where":[332],"Trileptal":[333],"is":[334],"already":[337],"registered.":[338]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}